An FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury in severe COVID-19 cases, according to a preclinical study from researchers at Weill Cornell Medicine and Cold Spring Harbor Laboratory.
An FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury in severe COVID-19 cases, according to a preclinical study from researchers at Weill Cornell Medicine and Cold Spring Harbor Laboratory.
